REPORT ID 13355

United States Non-Tyrosine Kinase Inhibitors Market Report 2017

Publish Date
21-Nov-17
Pages
113
Format
Electronic (PDF)

In this report, the United States Non-Tyrosine Kinase Inhibitors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Non-Tyrosine Kinase Inhibitors in these regions, from 2012 to 2022 (forecast).

United States Non-Tyrosine Kinase Inhibitors market competition by top manufacturers/players, with Non-Tyrosine Kinase Inhibitors sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Roche
    Eli Lilly
    Novartis
    Array BioPharma
    Nerviano Medical Sciences
    Pfizer
    Merck KGaA
    Astex Pharmaceuticals
    Cyclacel Pharmaceuticals
    Daiichi Sankyo
    Onconova Therapeutics
    AstraZeneca
    GlaxoSmithKline (GSK)
    Carna Biosciences
    Celgene Corporation
    Eternity Bioscience
    Jasco Pharmaceuticals

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    mTOR Inhibitors
    RAF/MEK Inhibitors
    CDK Inhibitors
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Liver Cancer
    Respiratory Cancer
    Brain Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Non-Tyrosine Kinase Inhibitors Market Report 2017
1 Non-Tyrosine Kinase Inhibitors Overview
    1.1 Product Overview and Scope of Non-Tyrosine Kinase Inhibitors
    1.2 Classification of Non-Tyrosine Kinase Inhibitors by Product Category
        1.2.1 United States Non-Tyrosine Kinase Inhibitors Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Non-Tyrosine Kinase Inhibitors Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 mTOR Inhibitors
        1.2.4 RAF/MEK Inhibitors
        1.2.5 CDK Inhibitors
    1.3 United States Non-Tyrosine Kinase Inhibitors Market by Application/End Users
        1.3.1 United States Non-Tyrosine Kinase Inhibitors Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Liver Cancer
        1.3.3 Respiratory Cancer
        1.3.4 Brain Cancer
        1.3.5 Others
    1.4 United States Non-Tyrosine Kinase Inhibitors Market by Region
        1.4.1 United States Non-Tyrosine Kinase Inhibitors Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Non-Tyrosine Kinase Inhibitors Status and Prospect (2012-2022)
        1.4.3 Southwest Non-Tyrosine Kinase Inhibitors Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Non-Tyrosine Kinase Inhibitors Status and Prospect (2012-2022)
        1.4.5 New England Non-Tyrosine Kinase Inhibitors Status and Prospect (2012-2022)
        1.4.6 The South Non-Tyrosine Kinase Inhibitors Status and Prospect (2012-2022)
        1.4.7 The Midwest Non-Tyrosine Kinase Inhibitors Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Non-Tyrosine Kinase Inhibitors (2012-2022)
        1.5.1 United States Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2012-2022)
        1.5.2 United States Non-Tyrosine Kinase Inhibitors Revenue and Growth Rate (2012-2022)

2 United States Non-Tyrosine Kinase Inhibitors Market Competition by Players/Suppliers
    2.1 United States Non-Tyrosine Kinase Inhibitors Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Non-Tyrosine Kinase Inhibitors Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Non-Tyrosine Kinase Inhibitors Average Price by Players/Suppliers (2012-2017)
    2.4 United States Non-Tyrosine Kinase Inhibitors Market Competitive Situation and Trends
        2.4.1 United States Non-Tyrosine Kinase Inhibitors Market Concentration Rate
        2.4.2 United States Non-Tyrosine Kinase Inhibitors Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Non-Tyrosine Kinase Inhibitors Manufacturing Base Distribution, Sales Area, Product Type

3 United States Non-Tyrosine Kinase Inhibitors Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Non-Tyrosine Kinase Inhibitors Sales and Market Share by Region (2012-2017)
    3.2 United States Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Region (2012-2017)
    3.3 United States Non-Tyrosine Kinase Inhibitors Price by Region (2012-2017)

4 United States Non-Tyrosine Kinase Inhibitors Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Non-Tyrosine Kinase Inhibitors Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Type (2012-2017)
    4.3 United States Non-Tyrosine Kinase Inhibitors Price by Type (2012-2017)
    4.4 United States Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Type (2012-2017)

5 United States Non-Tyrosine Kinase Inhibitors Sales (Volume) by Application (2012-2017)
    5.1 United States Non-Tyrosine Kinase Inhibitors Sales and Market Share by Application (2012-2017)
    5.2 United States Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Non-Tyrosine Kinase Inhibitors Players/Suppliers Profiles and Sales Data
    6.1 Roche
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Eli Lilly
        6.2.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis
        6.3.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Array BioPharma
        6.4.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Nerviano Medical Sciences
        6.5.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Pfizer
        6.6.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Merck KGaA
        6.7.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Astex Pharmaceuticals
        6.8.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Cyclacel Pharmaceuticals
        6.9.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Daiichi Sankyo
        6.10.2 Non-Tyrosine Kinase Inhibitors Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Onconova Therapeutics
    6.12 AstraZeneca
    6.13 GlaxoSmithKline (GSK)
    6.14 Carna Biosciences
    6.15 Celgene Corporation
    6.16 Eternity Bioscience
    6.17 Jasco Pharmaceuticals

7 Non-Tyrosine Kinase Inhibitors Manufacturing Cost Analysis
    7.1 Non-Tyrosine Kinase Inhibitors Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Non-Tyrosine Kinase Inhibitors

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Non-Tyrosine Kinase Inhibitors Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Non-Tyrosine Kinase Inhibitors Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Non-Tyrosine Kinase Inhibitors Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Non-Tyrosine Kinase Inhibitors Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Non-Tyrosine Kinase Inhibitors Sales Volume Forecast by Type (2017-2022)
    11.3 United States Non-Tyrosine Kinase Inhibitors Sales Volume Forecast by Application (2017-2022)
    11.4 United States Non-Tyrosine Kinase Inhibitors Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer